Home LiteratureArticle Details
PMID: 6352003 Published · ppublish English Clinical Trial Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update.

Cancer ·Vol. 52 ·No. 9 ·1983-11-01 ·Pages 1551-7

Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER, Cruz AB, Foster R, Gardner B, Lerner H, Margolese R

Abstract

The current findings completely affirm the validity of our original observations indicating the appropriateness of grouping primary breast cancer patients into those with negative, 1 to 3, or greater than or equal to 4 positive nodes. Results, however, reveal that there is a risk in combining all patients with greater than or equal to 4 positive nodes into a single group. Since there was a 25% greater disease-free survival and an 18% greater survival in those with 4 to 6 than in those with greater than or equal to 13 positive axillary nodes, such a unification may provide misleading information regarding patient prognosis, as well as the worth of a therapeutic regimen when compared with another from a putatively similar patient population. Of particular interest were findings relating the conditional probability, i.e., the hazard rate, of a treatment failure or death each year during the 5-year period following operation to nodal involvement with tumor. Whereas the hazard rate for those with negative, or 1 to 3 positive nodes, was relatively low and constant, in those with greater than or equal to 4 positive nodes the risk in the early years was much greater, but by the fifth year it was similar to that occurring when 1-3 nodes were involved, and not much different from negative node patients. The same pattern existed whether 4 to 6 or greater than or equal to 13 nodes were positive. When the current findings are considered relative to other factors with predictive import, it is concluded that nodal status still remains the primary prognostic discriminant.

MeSH Terms
Axilla Breast Neoplasms/mortality,pathology,therapy Clinical Trials as Topic Female Follow-Up Studies Humans Lymph Nodes/pathology Mastectomy Middle Aged Probability Prognosis
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Fisher B
Bauer M
Wickerham D L
Redmond C K
Fisher E R
Cruz A B
Foster R
Gardner B
Lerner H
Margolese R
Article Info
Journal
Cancer
Abbr.
Cancer
ISSN
0008-543X
Published
1983-11-01
Pages
1551-7
Language
English
Region
United States
NLM ID
0374236
Subset
IM
Grants
NCI NIH HHS · N01-CB-23876 · United States
NCI NIH HHS · R-01-CA-12027 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]